Background: Adverse effects from childhood leukemia treatment may persist or present years after cure from cancer. We provide a comprehensive evaluation of subsequent hospitalization in five-year survivors of childhood acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).
Methods: In the Adult Life after Childhood Cancer in Scandinavia Study, we identified 4003 five-year survivors diagnosed with childhood leukemia 1970-2008 in Denmark, Sweden, Iceland, and Finland. Survivors and 129 828 population comparisons were followed for first-time nonpsychiatric hospitalizations for 120 disease categories in the hospital registries. Standardized hospitalization rate ratios and absolute excess rates were calculated. All statistical tests were two-sided.
Results: Survivors of ALL (n = 3391), AML (n = 389), and CML (n = 92) had an increased overall hospitalization rate compared with population comparisons. The rate ratio for any hospitalization was 1.95 (95% confidence interval [CI] = 1.83 to 2.07) in ALL, 3.09 (95% CI = 2.53 to 3.65) in AML, and 4.51 (95% CI = 3.03 to 6.00) in CML survivors and remained increased even 20 years from leukemia diagnosis. Corresponding absolute excess rates per 1000 person-years were 28.48 (95% CI = 24.96 to 32.00), 62.75 (95% CI = 46.00 to 79.50), and 105.31 (95% CI = 60.90 to 149.72).
Conclusion: Leukemia survivors have an increased rate of hospitalization for medical conditions. We provide novel insight into the relative and absolute rate of hospitalization for 120 disease categories in survivors of ALL, AML, and CML, which are likely to be informative for both survivors and healthcare providers.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748786 | PMC |
http://dx.doi.org/10.1093/jnci/djz016 | DOI Listing |
Cancers (Basel)
January 2025
Department of Haematology and Oncology, University Children's Hospital, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany.
Background: The incorporation of anti-GD2 antibodies such as ch14.18/SP2/0 into the multimodal treatment of high-risk neuroblastoma (HR-NB) patients has improved their outcomes. As studies assessing the long-term outcomes, long-term sequelae, and health-related quality of life (HRQoL) of this treatment are limited, this retrospective analysis aimed to explore these.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Division of Endocrinology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Importance: Data characterizing the severity and changing prevalence of bone mineral density (BMD) deficits and associated nonfracture consequences among childhood cancer survivors decades after treatment are lacking.
Objective: To evaluate risk for moderate and severe BMD deficits in survivors and to identify long-term consequences of BMD deficits.
Design, Setting, And Participants: This cohort study used cross-sectional and longitudinal data from the St Jude Lifetime (SJLIFE) cohort, a retrospectively constructed cohort with prospective follow-up.
J Natl Cancer Inst
January 2025
Division of Pediatric Hematology & Oncology, University of Minnesota, Minneapolis, MN, USA.
Purpose: It is not known whether temporal changes in childhood cancer therapy have reduced risk of subsequent malignant neoplasms (SMNs) of the central nervous system (CNS), a frequently fatal late effect of cancer therapy.
Methods: Five-year survivors of primary childhood cancers diagnosed between 1970-1999 in the Childhood Cancer Survivor Study with a subsequent CNS SMN were identified. Cumulative incidence rates and standardized incidence ratios (SIR) were compared among survivors diagnosed between 1970-1979 (N = 6223), 1980-1989 (N = 9680), and 1990-1999 (N = 8999).
Eur Arch Otorhinolaryngol
December 2024
All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India.
Aust J Gen Pract
December 2024
MB BChir (Cantab), MA (Med) (Cantab), FRCS (Eng), FRACS (OHNS), Consultant Otolaryngologist, Head and Neck Surgeon, Royal Brisbane and Women@s Hospital/Surgical, Treatment and Rehabilitation Service, Brisbane, Qld; Deputy Director of Surgery, Surgical, Treatment@and Rehabilitation Service, Brisbane, Qld; Adjunct Associate Professor, Griffith Institute of Drug Discovery, Griffith University, Brisbane, Qld; Senior Academic Lecturer, School of Clinical Medicine, The@University of Queensland, Brisbane, Qld.
Background: A head and neck cancer patient has completed treatment and five-year surveillance with their oncologists and surgeons and has been discharged back into your care. What is next and what do you not want to miss in this patient?
Objective: This article aims to provide the general practitioner with a practical guide and an up-to-date evidence-based review on how to manage the head and neck cancer survivor.
Discussion: Attentive surveillance encompassing risk stratification and guidance, early detection of recurrence and second malignancies, effective management of chronic symptoms and the provision of psychosocial support are fundamental in providing a holistic and comprehensive care plan for the head and neck cancer survivor.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!